Previous literature focused on the dosage of ghrelin in patients with CeD, described a higher level of this peptide in CeD patients at diagnosis and a lower level in patients on a GFD [28,29], probably due to the changes in the nutritional state [30] or to the reduction of systemic inflammation after diagnosis [31]. Here, GHRL is linked to cranioectodermal dysplasia.